ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Twenty-Four-Week UACR Response Trajectories and Clinical Correlates of Residual Albuminuria in Diabetic Kidney Disease During Finerenone Therapy: A Real-World Longitudinal Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: After finerenone therapy, some patients with diabetic kidney disease (DKD) continue to have residual albuminuria. A single time-point change in urinary albumin-to-creatinine ratio (UACR) may not fully capture response heterogeneity in real-world practice. This study aimed to identify 24-week baseline-corrected UACR response trajectories in patients with DKD and residual albuminuria during finerenone therapy and to examine associated clinical factors. Methods: This single-center retrospective real-world longitudinal cohort study included 136 patients with DKD who had residual albuminuria after at least 4 weeks of finerenone therapy and available longitudinal UACR data. Based on multi-time-point log(UACR_t/UACR_baseline) data over 24 weeks, latent class mixed models were used to identify UACR response trajectories and analyze clinical factors associated with the persistent residual albuminuria trajectory. Results: Three UACR response trajectories were identified: favorable response in 43 patients (31.6%), partial response in 62 patients (45.6%), and persistent residual albuminuria in 31 patients (22.8%); the latter 2 patterns accounted for 68.4% of the selected residual-albuminuria cohort. The median relative changes in UACR at week 24 were -51.6%, -24.8%, and -4.9%, respectively. Higher HbA1c was associated with higher estimated odds of the persistent residual albuminuria trajectory (OR, 1.46; 95% CI, 1.07-2.00). The estimated directions for systolic blood pressure and sodium-glucose cotransporter 2 (SGLT2) inhibitor use were consistent, although uncertainty remained in extended or selected sensitivity analyses. Week-24 eGFR changes did not differ clearly across trajectories, and continuous UACR change was not clearly associated with eGFR change. Conclusion: Patients with DKD and residual albuminuria during finerenone therapy showed distinct 24-week UACR response trajectories. Trajectory analysis provides exploratory real-world evidence for dynamic risk stratification, but the identified patterns and clinical correlates require validation in larger, prospective, multicenter cohorts with longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.